Filgrastim + Plerixafor for Bone Marrow Failure Syndrome

This trial examines the safety and feasibility of collecting hematopoietic stem and progenitor cells (HSPCs) from individuals with bone marrow failure syndromes. The study uses two drugs: Filgrastim, which stimulates white blood cell production, and Plerixafor, which mobilizes stem cells into the bloodstream for collection. These collected cells may be used in future gene therapy. This trial suits individuals with a genetic type of bone marrow failure syndrome who can donate cells for research and have not undergone a prior bone marrow transplant. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking research.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that using Filgrastim and Plerixafor together is generally safe. Studies have found that this combination effectively mobilizes stem cells, with side effects that are usually manageable. Most side effects are mild, such as nausea, fatigue, or slight bone pain. Serious side effects are rare but can occur. For instance, in a study with a similar drug combination, some patients experienced serious issues like disease progression or transplant complications, though these were not directly linked to the treatment. Overall, this combination has been used successfully in other contexts, indicating it is a safe choice for many patients.¹²³⁴⁵

Researchers are excited about the combination of Filgrastim and Plerixafor for bone marrow failure syndrome because it introduces a novel method to mobilize and collect stem cells more effectively. Unlike standard treatments that primarily focus on managing symptoms, this approach aims to gather CD34+ hematopoietic stem and progenitor cells (HSPCs) through apheresis, which could potentially pave the way for future gene therapy applications. This method not only offers a new way to address the root cause of the condition but also holds promise for advancing research into long-term, curative treatments.

Research has shown that using Filgrastim and Plerixafor together effectively gathers stem cells, crucial for treating conditions like bone marrow failure syndromes (BMFS). In this trial, participants will receive a combination of Filgrastim and Plerixafor to facilitate the collection of CD34+ HSPCs via apheresis. Studies have found that Plerixafor, when combined with Filgrastim, aids in collecting these vital cells even in patients who struggled with other methods. In some cases, this combination successfully mobilized stem cells in up to 80% of individuals with similar conditions. This increased mobilization ensures enough stem cells are collected for potential treatments, such as gene therapy. Overall, this combination shows promise for collecting stem cells in challenging cases.¹³⁴⁶⁷